GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Notes Receivable

Aroa Biosurgery (ASX:ARX) Notes Receivable : A$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Notes Receivable?

Aroa Biosurgery's Notes Receivable for the quarter that ended in Mar. 2024 was A$0.00 Mil.


Aroa Biosurgery Notes Receivable Historical Data

The historical data trend for Aroa Biosurgery's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Notes Receivable Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Notes Receivable
- - - - -

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Notes Receivable Get a 7-Day Free Trial - - - - -

Aroa Biosurgery Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Aroa Biosurgery Notes Receivable Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Aroa Biosurgery (ASX:ARX) Business Description

Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines